联合或单药伊匹单抗作为晚期黑色素瘤的免疫疗法：一项批判性综述。
Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.
作者信息
Abdel-Rahman Omar
机构信息
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo 11665, Egypt.
出版信息
Melanoma Manag. 2016 Sep;3(3):231-243. doi: 10.2217/mmt-2016-0011. Epub 2016 Aug 22.
AIM
A pooled analysis of the efficacy and toxicity of combination immunotherapy versus single-agent ipilimumab in the management of advanced melanoma has been conducted.
METHODOLOGY
Eligible studies included randomized controlled studies evaluating ipilimumab-based doublet immunotherapy versus ipilimumab monotherapy for the management of unresectable melanoma.
RESULTS
Nivolumab/ipilimumab combination strategy is associated with a significant improvement in objective response rate (odds ratio: 7.38; 95% CI: 3.71-14.67; p < 0.00001) and progression-free survival (0.42; 95% CI: 0.34-0.52; p < 0.00001) as well as a higher relative risk for high-grade elevated alanine aminotransferase (5.58; 95% CI: 2.28-13.67; p = 0.0002).
CONCLUSION
This analysis demonstrated that nivolumab/ipilimumab combination is associated with a higher objective response rate and progression-free survival in the management of advanced melanoma.
目的
已对联合免疫疗法与单药伊匹木单抗治疗晚期黑色素瘤的疗效和毒性进行了汇总分析。
方法
符合条件的研究包括评估基于伊匹木单抗的双联免疫疗法与伊匹木单抗单药疗法治疗不可切除黑色素瘤的随机对照研究。
结果
纳武单抗/伊匹木单抗联合策略与客观缓解率显著提高（优势比：7.38；95%置信区间：3.71 - 14.67；p < 0.00001）、无进展生存期（0.42；95%置信区间：0.34 - 0.52；p < 0.00001）相关，同时谷丙转氨酶升高的高级别相对风险更高（5.58；95%置信区间：2.28 - 13.67；p = 0.0002）。
结论
该分析表明，纳武单抗/伊匹木单抗联合疗法在晚期黑色素瘤治疗中具有更高的客观缓解率和无进展生存期。
Zotero 插件